# Heterogeneity and optimal study design between cell lines in induced pluripotent stem cell-based cardiac disease modeling

**Authors:** Renee G C Maas, Chris Denning, Joost P G Sluijter

PMC · DOI: 10.1093/stcltm/szag001 · Stem Cells Translational Medicine · 2026-01-28

## TL;DR

This paper reviews how variability between cell lines affects the reliability of heart disease models using stem cells, highlighting the need for better study design.

## Contribution

The paper provides meta-analyses of hiPSC-CM studies to quantify variability and guide optimal experimental design.

## Key findings

- Published studies using 4 or more hiPSC lines still show high heterogeneity in functional parameters.
- Variation between cell lines exceeds the effect of mutations, drug responses, or toxicity in some readouts.
- The study emphasizes the importance of selecting stable hiPSC lines and controls for reliable results.

## Abstract

Human-induced pluripotent stem cell (hiPSC) technologies have provided access to in vitro models of inaccessible human cardiomyocytes (CMs), providing new insights into human disease mechanisms, therapy strategies, and cardiac toxicology. However, the robustness of reproducible outcomes and integration of data among research groups are hampered due to the variation between cell lines, clones, and batches-to-batch differences. These variable outcomes in hiPSC models are caused by differences in human donors, genetic stability, and experimental variability, which affect morphology, cellular heterogeneity, transcript and protein abundance, and differentiation potency. This review summarizes the usage of hiPSC-CMs obtained from multiple lines and evaluates the corresponding experimental variation between studies to perform in-depth in vitro power calculations. Our meta-analyses show that although 4 or more hiPSC lines are used in 21 published case-control studies, these reports still contain high heterogeneity between functional parameters. In specific CM readouts, the SD is >40%, meaning that the variation between different cell lines is larger than the effect of the studied mutation, drug response, or toxicity. Results indicate a need for careful selection of hiPSC lines, controls, and readout stability and these insights will further guide the power of hiPSC lines in biomedical applications.

Graphical Abstract

## Full-text entities

- **Genes:** MYBPC3 (myosin binding protein C3) [NCBI Gene 4607] {aka CMD1MM, CMH4, FHC, LVNC10, MYBP-C, cMyBP-C}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, TNNT2 (troponin T2, cardiac type) [NCBI Gene 7139] {aka CMD1D, CMH2, CMPD2, LVNC6, RCM3, TnTC}, MYH7 (myosin heavy chain 7) [NCBI Gene 4625] {aka CMD1S, CMH1, CMYO7A, CMYO7B, CMYP7A, CMYP7B}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, TPM1 (tropomyosin 1) [NCBI Gene 7168] {aka C15orf13, CMD1Y, CMH3, HEL-S-265, HTM-alpha, LVNC9}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, ERG (ETS transcription factor ERG) [NCBI Gene 2078] {aka LMPHM14, erg-3, p55}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, KCNQ1 (potassium voltage-gated channel subfamily Q member 1) [NCBI Gene 3784] {aka ATFB1, ATFB3, JLNS1, KCNA8, KCNA9, KVLQT1}
- **Diseases:** toxicity (MESH:D064420), ventricular tachycardia (MESH:D017180), lysosomal storage disorders (MESH:D016464), SD (MESH:D012735), DCM (MESH:D002311), HT (MESH:D008228), arrhythmogenic cardiomyopathy (MESH:D019571), EHT (MESH:D006331), CTiD (MESH:D000075902), non-compaction cardiomyopathy (MESH:D056830), DMD (MESH:D020388), HCM (MESH:D002312), arrhythmia (MESH:D001145), cardiomyopathies (MESH:D009202), cardiac toxicity (MESH:D066126), QT prolongation (MESH:D008133), hypertrophy (MESH:D006984)
- **Chemicals:** Quinidine (MESH:D011802), Trastuzumab (MESH:D000068878), calcium (MESH:D002118), Isoproterenol (MESH:D007545), Na2+ (MESH:C033479), dofetilide (MESH:C063533), Ca2+ (-), tetrodotoxin (MESH:D013779), potassium (MESH:D011188), Mox (MESH:D000077266)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** END-2 — Homo sapiens (Human), Endometrial undifferentiated carcinoma, Cancer cell line (CVCL_B5KE)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866806/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866806/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866806/full.md

---
Source: https://tomesphere.com/paper/PMC12866806